Authors : Nitin S Kolhe, V H Bhaskar, Shubham Ghosh, Sanskruti Kharavtekar, Savni Prabhu, Prathamesh Gangurde, Prachi Navale
DOI : 10.18231/j.jpbs.2021.014
Volume : 9
Issue : 2
Year : 2021
Page No : 103-111
A widespread increase in the prevalence of fungal infections has been documented in recent decades. Candida albicans infections, which are frequently refractory and linked with high morbidity and mortality, place a significant burden on public health, despite the fact that existing antifungal medicines are restricted and associated with toxicity. Fungi are one of the most underappreciated killers, as evidenced by the fact that Amphotericin B and other commercially available antifungal therapies are still recognized as gold standards. The majority of commonly used antifungal medications have toxicity, effectiveness, and cost disadvantages. As a result of these limitations, there is a growing demand for the development of a novel antifungal medication treatment that acts selectively on new targets while having the fewest adverse effects. Natural goods, whether as pure phytocompounds or regulated plant extracts, give prospects for the development of lead compounds that may subsequently be turned into diverse synthetic medications with the appropriate alterations. These herbs can also be used as a component of a herbal synthetic combination, lowering the minimum required dose of the synthetic medicine (when taken singly) and reducing the risk of adverse effects. The goal of this research is to reduce the minimum required concentrations of today's antifungal medications by mixing them with a few less well-known herbal extracts while maintaining their efficacy.
Keywords: Amphotericin B, Antifungal, Phytocompounds